Comparing Moderna’s mRNA-1083 and Pfizer’s dual-target mRNA vaccines for influenza and COVID-19

Abstract This review examines Moderna’s mRNA-1083 and Pfizer/BioNTech’s mRNA-1020/1030 dual-target vaccines for COVID-19 and influenza. Both utilize mRNA technology, demonstrating strong immunogenicity and favorable safety profiles. Moderna’s mRNA-1083 showed superior immune responses, while Pfizer’...

Full description

Saved in:
Bibliographic Details
Main Authors: Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Courage Idahor, Petra Mariaria, Favour Peters, Raolat Adenike Salami, Olajide Ojo, Emmanuel Nwaeze, Owolabi Abdullahi, Joel Chuku
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-025-01145-6
Tags: Add Tag
No Tags, Be the first to tag this record!